Research Article
Efficacy and Safety of an Ophthalmic DMPC-Based Nanoemulsion in Patients with Dry Eye Disease: A Phase I/II Randomized Clinical Trial
Figure 4
Treatment-related adverse events in ITT population (nā=ā126). Causality assessment versus expectedness. At the end of phase II, for control group at least 1% of total unexpected AE were related to treatment vs. 4.9% for PRO-176. No statistically significant differences were found between control and PRO-176, in all comparisons.